Unknown

Dataset Information

0

Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish.


ABSTRACT:

Background

Mycobacterium abscessus is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments.

Objectives

To identify drug candidates that exhibit synergistic activity with clarithromycin against M. abscessus.

Methods

We performed cell-based phenotypic screening of a compound library against M. abscessus induced to become resistant to clarithromycin. Furthermore, we evaluated the toxicity and efficacy of the top compound in a zebrafish embryo infection model.

Results

The screen revealed rifaximin as a clarithromycin potentiator. The combination of rifaximin and clarithromycin was synergistic and bactericidal in vitro and potent in the zebrafish model.

Conclusions

The data indicate that the rifaximin/clarithromycin combination is promising to effectively treat pulmonary NTM infections.

SUBMITTER: Goh BC 

PROVIDER: S-EPMC10164658 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rifaximin potentiates clarithromycin against <i>Mycobacterium abscessus in vitro</i> and in zebrafish.

Goh Boon Chong BC   Larsson Simon S   Dam Linh Chi LC   Ling Yan Han Sharon YHS   Chua Wei Lin Patrina WLP   Abirami R R   Singh Samsher S   Ong Jun Long Ernest JLE   Teo Jeanette W P JWP   Ho Peiying P   Ingham Philip W PW   Pethe Kevin K   Dedon Peter C PC  

JAC-antimicrobial resistance 20230508 3


<h4>Background</h4><i>Mycobacterium abscessus</i> is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments.<h4>Objectives</h4>To identify drug candidates that exhibit synergistic activity with clarit  ...[more]

Similar Datasets

| S-EPMC8693020 | biostudies-literature
| S-EPMC5700366 | biostudies-literature
| S-EPMC8592419 | biostudies-literature
| S-EPMC11486469 | biostudies-literature
2025-05-06 | PXD047862 | Pride
| S-EPMC5192163 | biostudies-literature
| S-EPMC4598034 | biostudies-literature
| S-EPMC6325232 | biostudies-literature
| S-EPMC8555507 | biostudies-literature
| S-EPMC7778363 | biostudies-literature